Table I.
Characteristics of Included Studies (n=13)
| Study | Location | Cohort Description | Anxiety Evaluation Method | Study Type | Anxiety Prevalence | Adherence Evaluation Method | Poor Adherence Prevalence |
|---|---|---|---|---|---|---|---|
| Nguyen et al. 2016[32] | Vietnam | 1050 HIV + adults, on ART >6 months | EQ-5D-5L | Cross-Sectional | 43.8% | 30 Day VAS Scale | 30.9% |
| Joshi et al. 2014[34] | India | 2924 HIV+ adults, mix of newly initiating ART and on ART for >6 months | Hospital Anxiety and Depression Scale (HADS) | Cross-Sectional | 69.8% | AACTG Questionnaire | 24.0% |
| Guimares et al. 2008[35] | Brazil | 350 HIV+ adults initiating ART | Hospital Anxiety and Depression Scale (HADS) | Prospective Cohort | 36.0% | Patient Interview | 51.4% |
| Nel et al 2013[33] | South Africa | 101 HIV + adults, on ART >6 months | Beck’s Anxiety Inventory | Cross-Sectional | 28.7% | Six Item Self-Reporting Questionnaire | 45.5% |
| Adejumo et al. 2016[36] | Nigeria | 453 HIV + adults, on ART >6 months | Composite International Diagnostic Instrument (CIDI) | Cross-Sectional | 2.5% | 1 week and 1 month self-reported missed doses | 9.7% |
| Yunusa et al. 2014[37] | Nigeria | 159 HIV + adults, on ART >6 months | Hospital Anxiety and Depression Scale | Cross-Sectional | 17.1% | Self-reported pattern of adherence | 5.7% |
| Pefura-Yone et al. 2013[38] | Cameroon | 889 HIV + adults, on ART >6 months | GAD-7, Self-Administered | Cross-Sectional | 11.1% | Antiretroviral Medication Self-Report 7-day recall | 22.5% |
| Tao et al. 2017[39] | China | 228 HIV+ MSM on ART >6 months | Hospital Anxiety and Depression Scale | Prospective Cohort | 49.0% | Self-reported missed doses over last 3 months | 8.0% |
| Prasithsirikul et al. 2017[31] | Thailand | 2023 HIV + adults, on ART >6 months | Hospital Anxiety and Depression Scale | Cross-Sectional | 4.5% | >90% Self-Reported Dose Adherence | 14.0% |
| Yu et al 2018[40] | China | 207 newly diagnosed HIV+ adults initiating ART | GAD-7 | Cross-Sectional | 29.5% | CPCRA Antiretroviral Medications Self-Report Questionnaire | 14.5% |
| Pokhrel et al 2018[41] | Nepal | 655 HIV+ adults, on ART >1 year | Comprehensive International Diagnostic Interview-Short Form (CIDI-SF) | Randomized Controlled Trial | 11.6% | AACTG Questionnaire | 19.0% |
| Campos et al. 2008[29]* | Brazil | 293 H HIV + adults, on ART >6 months | Hospital Anxiety and Depression Scale | Prospective Cohort | 12.6% | >95% Self-Reported 3 day dose adherence | 37.2% |
| Qiao et al. 2015[30]* | China | 1254 HIV + adults, on ART >6 months | Zung Self-Rating Anxiety Scale | Cross-Sectional | Not reported | AACTG Questionnaire | Not Reported |
*
Not included in the final meta-analysis